Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.53 CAD | +2.62% | +8.95% | +27.44% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 57% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.44% | 985M | D- | ||
+35.04% | 5.92B | B- | ||
-15.13% | 4.51B | C+ | ||
-9.75% | 3.15B | B- | ||
+2.14% | 3.1B | C | ||
-6.82% | 2.42B | - | D+ | |
+47.87% | 1.97B | - | ||
-7.89% | 1.68B | - | - | |
+0.09% | 1.65B | - | - | |
-12.97% | 1.53B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRON Stock
- Ratings Cronos Group Inc.